XML 16 R6.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Stockholders' Equity - USD ($)
$ in Millions
Total
Common Stock [Member]
Additional paid-in capital [Member]
Accumulated other comprehensive loss [Member]
Retained earnings (accumulated deficit) [Member]
Myriad Genetics, Inc. Stockholders' equity [Member]
Noncontrolling Interest [Member]
Beginning Balance at Jun. 30, 2017 $ 768.0 [1] $ 0.7 $ 851.4 $ (5.5) [1] $ (78.2) [1] $ 768.4 [1] $ (0.4)
Issuance of common stock under share-based compensation plans 1.7   1.7     1.7  
Share-based payment expense 6.4   6.4     6.4  
Non-controlling interest 0.1           0.1
Net income (loss) 78.9       78.9 78.9  
Other comprehensive income, net of tax 3.3     3.3   3.3  
Ending Balance at Sep. 30, 2017 858.4 0.7 859.5 (2.2) 0.7 858.7 (0.3)
Beginning Balance at Jun. 30, 2017 768.0 [1] 0.7 851.4 (5.5) [1] (78.2) [1] 768.4 [1] (0.4)
Net income (loss) [1] 118.9            
Ending Balance at Mar. 31, 2018 932.8 0.7 889.5 1.8 40.7 932.7 0.1
Beginning Balance at Sep. 30, 2017 858.4 0.7 859.5 (2.2) 0.7 858.7 (0.3)
Issuance of common stock under share-based compensation plans 4.6   4.6     4.6  
Share-based payment expense 6.9   6.9     6.9  
Non-controlling interest 0.3           0.3
Net income (loss) 30.9       30.9 30.9  
Other comprehensive income, net of tax (0.2)     (0.2)   (0.2)  
Ending Balance at Dec. 31, 2017 900.9 0.7 871.0 (2.4) 31.6 900.9  
Issuance of common stock under share-based compensation plans 11.9   11.9     11.9  
Share-based payment expense 6.6   6.6     6.6  
Non-controlling interest 0.1           0.1
Net income (loss) 9.1 [1]       9.1 9.1  
Other comprehensive income, net of tax 4.2     4.2   4.2  
Ending Balance at Mar. 31, 2018 932.8 0.7 889.5 1.8 40.7 932.7 0.1
Beginning Balance at Jun. 30, 2018 966.1 [1] 0.7 915.4 (4.1) [1] 54.1 [1] 966.1 [1]  
Issuance of common stock under share-based compensation plans 1.9   1.9     1.9  
Issuance of common stock for acquisition 127.4   127.4     127.4  
Share-based payment expense 7.7   7.7     7.7  
Net income (loss) (0.7)       (0.7) (0.7)  
Other comprehensive income, net of tax (0.2)     (0.2)   (0.2)  
Ending Balance at Sep. 30, 2018 1,102.2 0.7 1,052.4 (4.3) 53.4 1,102.2  
Beginning Balance at Jun. 30, 2018 966.1 [1] 0.7 915.4 (4.1) [1] 54.1 [1] 966.1 [1]  
Net income (loss) 8.8            
Ending Balance at Mar. 31, 2019 1,081.7 0.7 1,057.0 (5.7) 29.8 1,081.8 (0.1)
Beginning Balance at Sep. 30, 2018 1,102.2 0.7 1,052.4 (4.3) 53.4 1,102.2  
Issuance of common stock under share-based compensation plans 2.6   2.6     2.6  
Share-based payment expense 7.5   7.5     7.5  
Repurchase and retirement of common stock (50.0)   (16.9)   (33.1) (50.0)  
Non-controlling interest (0.1)           (0.1)
Net income (loss) 2.6       2.6 2.6  
Other comprehensive income, net of tax (0.7)     (0.7)   (0.7)  
Ending Balance at Dec. 31, 2018 1,064.1 0.7 1,045.6 (5.0) 22.9 1,064.2 (0.1)
Issuance of common stock under share-based compensation plans 1.9   1.9     1.9  
Share-based payment expense 9.5   9.5     9.5  
Net income (loss) 6.9       6.9 6.9  
Other comprehensive income, net of tax (0.7)     (0.7)   (0.7)  
Ending Balance at Mar. 31, 2019 $ 1,081.7 $ 0.7 $ 1,057.0 $ (5.7) $ 29.8 $ 1,081.8 $ (0.1)
[1] Amounts adjusted due to the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (Topic 606). See Note 1 to the financial statements contained in Part I, Item 1 of this report for additional information.